PRO115 antibody compositions and methods of use
The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.
1. An isolated monoclonal antibody which competes for binding to the same epitope as the epitope bound by the monoclonal antibody produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-7604 and PTA-7605 or which is produced by a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-7604 and PTA-7605.
2. The antibody of claim 1 which is an antibody binding fragment, a chimeric antibody, a human antibody or humanized antibody.
3. The antibody of claim 2 which is conjugated to a growth inhibitory agent or a cytotoxic agent.
4. The antibody of claim 3 wherein the cytotoxic agent is selected from the group consisting of toxins, antibiotics, radioactive isotopes and nucleolytic enzymes.
5. The antibody of claim 4 , wherein the toxin is selected from the group consisting of ricin, saponin, maytansinoid and calicheamicin.
6. The antibody of claim 3 where the antibody inhibits the growth of Pro115 (SEQ ID NO:66)-expressing cancer cells.
7. The antibody of claim 6 , wherein the cancer cells are from a cancer selected from the group consisting of prostate, colon, lung and pancreas cancer.
8. An isolated cell that produces the antibody of claim 1 .
9. The cell of claim 8 , wherein the cell is a hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-7604 and PTA-7605.
10. A composition comprising the antibody of claim 1 and a carrier.
11. The composition of claim 10 , wherein the antibody is an antibody binding fragment, a chimeric antibody, a human antibody or humanized antibody.
12. The composition of claim 11 , wherein the humanized antibody is a humanized form of an anti-Pro115 antibody produced by hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-7604 and PTA-7605.
13. An article of manufacture comprising a container and a composition contained therein, wherein the composition comprises an antibody of claim 1 .
14. A kit comprising the antibody of claim 1 .
15. The kit of claim 14 , wherein the antibody is an antibody binding fragment, a chimeric antibody, a human antibody or humanized antibody.
16. The kit of claim 14 , wherein the antibody is a monoclonal antibody produced by hybridoma selected from the group consisting of American Type Culture Collection accession number PTA-7604 and PTA-7605.
17. The kit of claim 14 wherein such antibody is labeled.
18. The kit of claim 14 further comprising a label or package insert.